• Explore /
  • Poster
  • / Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).

Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF).

Abstract Video & Slides Poster

Authors

null

Naveen Pemmaraju

The University of Texas MD Anderson Cancer Center, Houston, TX

Naveen Pemmaraju , Bart L. Scott , Michael R. Savona , Stephen T. Oh , Claire Harrison , Alessandro M. Vannucchi , Francesca Palandri , Haifa Kathrin Al-Ali , Marta Sobas , Mary Frances McMullin , Vikas Gupta , Ruben A. Mesa , Sarah Buckley , Karisse Roman-Torres , Srdan Verstovsek , Abdulraheem Yacoub

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders

Clinical Trial Registration Number

NCT02055781; NCT04884191

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7058)

DOI

10.1200/JCO.2022.40.16_suppl.7058

Abstract #

7058

Poster Bd #

289

Abstract Disclosures

Similar Posters

First Author: Lucia Masarova

First Author: Haris Ali

First Author: Manmeet Singh Ahluwalia

First Author: Haris Ali